Hep B Vaccine Immunity May Wane After 15 Years

2007 ◽  
Vol 37 (13) ◽  
pp. 17
Author(s):  
MIRIAM E. TUCKER
Keyword(s):  
Hep B ◽  
Vaccine Immunity

Acute Hep B Incidence Doubles With Diabetes

2011 ◽  
Vol 44 (5) ◽  
pp. 30
Author(s):  
MIRIAM E. TUCKER
Keyword(s):  
Hep B

Infektionsprophylaxe für Drogenkonsumenten im offenen Strafvollzug durch Vergabe steriler Einmalspritzen über Automaten

2001 ◽  
Vol 47 (1) ◽  
pp. 57-65 ◽  
Author(s):  
Axel Heinemann ◽  
Ulrike Gross
Keyword(s):  
Needle Sharing ◽  
Medizinisches Personal ◽  
Hep B

Fragestellung: Machbarkeit,Effizienz und Akzeptanz eines Pilotprojektes zur automatengestützten Vergabe von sterilen Einmalspritzen an intravenös drogenkonsumierende Insassen der Anstalt des offenen Vollzuges in Hamburg-Vierlande wurden untersucht. </P><P>Methodik: Insassen- wie Mitarbeiterperspektive wurden mittels quantitativ und qualitativ ausgerichteter sozialwissenschaftlicher und medizinischer Begleitforschung analysiert. </P><P> Ergebnisse: In einer retrospektiven Analyse vor Projektbeginn fanden sich im Gesamtkollektiv (nur bei i. v. Konsumenten) 5 (2) Hep. B- sowie 2 (0) Hep. C-Serokonversionen, die sich mit hoher Wahrscheinlichkeit in Haft ereignet hatten. Während des Pilotprojektes wurden Neuinfektionen von Teilnehmern nicht beobachtet. In der sozialwissenschaftlichen Begleitforschung berichteten viele Insassen über anhaltend praktiziertes Needle-Sharing, wenn auch im medizinisch untersuchten Studienkollektiv zumindest die angegebene Frequenz dieses Risikoverhaltens bei vielen Insassen deutlich sank. Hauptgrund waren häufige Automatendefekte. Bei den Vollzugsmitarbeitern stellte sich im Verlauf keine Verbesserung der Projektakzeptanz dar. Ein Sonderproblem war im Anstieg polyvalenten Beikonsums von Methadon-Substituierten zu sehen. </P><P> Schlussfolgerungen: Bei Ausweitung des Konzeptes auf andere, vergleichbare Anstalten sollte die Option der Handvergabe von Spritzen z. B. durch Drogenberater oder medizinisches Personal auch unter dem Gesichtspunkt der für einen Projekterfolg unabdingbaren Mitarbeiterakzeptanz aufgrund möglicher Vorteile der Selektivität und Kontrollierbarkeit bevorzugt wahrgenommen werden, auch unter Aufgabe des Vorteils der Anonymität eines automatengestützten Tauschprinzips.

Panel: Safety Data Needed for Hep B Vaccine

2012 ◽  
Vol 42 (20) ◽  
pp. 30
Author(s):  
ELIZABETH MECHCATIE
Keyword(s):  
Safety Data ◽  
Hep B

scholarly journals Effectiveness of Wellbeing Intervention for Chronic Kidney Disease (WICKD): results of a randomised controlled trial

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Kylie M. Dingwall ◽  
Michelle Sweet ◽  
Alan Cass ◽  
Jaquelyne T. Hughes ◽  
David Kavanagh ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Kidney Disease ◽  
Controlled Trial ◽  
Psychosocial Interventions ◽  
Mental Wellbeing ◽  
Indigenous Australians ◽  
Treatment As Usual ◽  
Randomised Controlled ◽  
Hep B ◽  
Distress Scale

Abstract Background End stage kidney disease (ESKD) is associated with many losses, subsequently impacting mental wellbeing. Few studies have investigated the efficacy of psychosocial interventions for people with ESKD and none exist for Indigenous people, a population in which the ESKD burden is especially high. Methods This three-arm, waitlist, single-blind randomised controlled trial examined efficacy of the Stay Strong App in improving psychological distress (Kessler distress scale; K10), depressive symptoms (adapted Patient Health Questionnaire; PHQ-9), quality of life (EuroQoL; EQ. 5D) and dialysis adherence among Indigenous Australians undergoing haemodialysis in central and northern Australia (Alice Springs and Darwin), with follow up over two 3-month periods. Effects of immediate AIMhi Stay Strong App treatment were compared with those from a contact control app (The Hep B Story) and treatment as usual (TAU). Control conditions received the Stay Strong intervention after 3 months. Results Primary analyses of the full sample (N = 156) showed statistically significant decreases in K10 and PHQ-9 scores at 3 months for the Hep B Story but not for the Stay Strong app or TAU. Restricting the sample to those with moderate to severe symptoms of distress or depression (K10 > =25 or PHQ-9 > =10) showed significant decreases in K10 and PHQ-9 scores for both Stay Strong and Hep B Story. No significant differences were observed for the EQ-5D or dialysis attendance. Conclusions Findings suggest that talking to people about their wellbeing and providing information relevant to kidney health using culturally adapted, locally relevant apps improve the wellbeing of people on dialysis. Further research is required to replicate these findings and identify active intervention components. Trial registration ACTRN12617000249358; 17/02/2017.

scholarly journals Will vaccine immunity last?

2020 ◽  
Vol 248 (3313-3314) ◽  
pp. 10-11
Author(s):  
Graham Lawton
Keyword(s):  
Vaccine Immunity

HBV, HCV, HIV & TB Prevalence in Injection Drug Users in Major Cities of Punjab, Pakistan- a Survey-Based Research Report

2021 ◽  
Author(s):  
Ghafran Ali ◽  
Kanza Ashfaq
Keyword(s):  
Hepatitis B ◽  
Injection Drug Users ◽  
Drug Users ◽  
Injection Drug ◽  
Intravenous Drug ◽  
Research Report ◽  
Intravenous Drug Users ◽  
Rehabilitation Center ◽  
Rehabilitation Centers ◽  
Hep B

Hepatitis-B,C,HIV and TB among intravenous drug users continues to be a serious explanation for disease and death, this study was conducted to survey the prevalence of Hepatitis-B,C,HIV and TB in rehabilitation center of Punjab, Pakistan. A telephonic and visited survey of 78 rehabilitation centers in Punjab Pakistan to assess their treatment. An analysis of 21 responded that returned useable data revealed that only 7.2% patients of responded rehabilitation centers are positive for HEP-B. 33.23% patients are positive for HEP-C, 8.74% patients are positive for HIV and 0.87% patients are positive for TB. Majority of the respondent of whom doctors, psychologists believe that the patient, partner of the patient and their children should be offered for HEP-B,C,HIV and TB screening regularly.

Intradermal hep B vaccine

2001 ◽  
Vol 9 (8) ◽  
pp. 363
Author(s):  
Cathel Kerr
Keyword(s):  
Hep B

scholarly journals STUDY OF PREVALENCE AND PATTERN OF HEARING LOSS IN PATIENTS OF HEPATITIS B

2019 ◽  
Vol 3 (12) ◽  
Author(s):  
Kapildev Mondal ◽  
Poulomi Saha
Keyword(s):  
Hearing Loss ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Pure Tone ◽  
Control Group ◽  
Hepatitis B Infection ◽  
Cellular Carcinoma ◽  
The Right ◽  
Hep B

Hepatitis B has been documented to cause various extra hepatic manifestations along with known hepatic complications. It has been reported that hepatitis-B patients are more susceptible to inner ear damage and hearing loss. The aim of this study is to evaluate hearing loss among patients of   hepatitis B {all 6 categories Hepatitis B infection: chronic Hepatitis B  infection , hepatitis B cirrhosis ,Hepatitis B virus carriers , occult chronic Hepatitis B and Hepatitis B infection with poly arthritis nodosa, hepato cellular carcinoma with hepatitis B}compared with healthy subjects. METHOD: In this case control study 100 Hepatitis B positive patients and 100 age and gender-matched healthy individuals were included over the period of 5 years. All of them were known cases of chronic hepatitis B positive for   HBsAg at least for 18 months. All   patients were aged 18 to 50 years to exclude presence of presbycusis. After base line investigations, they were subjected for all cases and controls were subjected otoscopic examination and hearing assessment using standard pure tone audiometry. Descriptive statistical analysis has been carried out in this study. RESULT: In patients of Hepatitis B (94 patients,6 patients had of  natural death ) pure tone average (mean thresholds 250,500, 1000,2000,4000 &8000 Hz) was 28.4 dB in the right ear and 27.3 dB in the left (hearing loss).In the control group(96 patients,4 patients dropped out), PTA average was 9.9 dB in the right ear and 9.3dB in the left (normal hearing). In both groups, Speech Discrimination score (SDS) was100% in both ears. The percentage of hearing loss in the right and left ear over the total of six frequencies differed significantly in the two groups. Out of 94 patients of control group, 38 patients (40.4%) patients presented with Chronic Liver Disease (CLD), 14 patients (14.8%) patients presented with cirrhosis with Hepatitis B, 6 (6.3%) patients had Poly arthritis Nodosa with Hep-B, 18(19.1%) patients were diagnosed as carrier of Hepatitis-B , 11(11.7%) patients had occult Hepatitis-B and 7(7.4%) patients were diagnosed with hepato cellular carcinoma. Hearing loss was maximum in patients of   PAN with Hep-B. Second highest mean SNHL was seen in patients of Hep-B with cirrhosis .Third highest mean hearing loss was noted in patients with HCC .Forth highest mean hearing loss was noted in patients with occult Hep-B. Fifth highest mean hearing loss was noted in carriers of Hep-B.Lowest group with SNHL was chronic liver disease. CONCLUSION: Regular audiometric tests are recommended for patients with HBV infection to assess their hearing ability and enable the earlier detection of SNHL. We also suggest that HBV presenting with the sudden onset of hearing loss should be examined for the possibility of acute exacerbation of chronic HBV infection. KEYWORDS: Mean, Sensorineural, Hearing loss, Cirrhosis.

Sign in / Sign up

Export Citation Format

Share Document